Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Feb 26, 2008

ADVENTRX, Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting

Feb. 7, 2008 - ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting, which takes place April 12 - 16, 2008 in San Diego, CA...
... ANX-530 is designed to reduce the incidence and severity of injection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer and has also shown activity in breast, ovarian, and other cancers...ADVENTRX's press Release-